The main factors driving market expansion for overactive bladder therapy are an increase in the elderly population and growing knowledge about treatments for overactive bladder syndrome. For instance, 1 in 3 persons over the age of 30 worldwide experienced nocturia in 2018, according to the National Association for Continence. Additionally, about 25 million Americans experienced urine incontinence in 2018, according to a data released by the U.S. Department of Health & Human Services.
According to the Brainy Insights forecast, the market for treatments for Overactive Bladder will increase to USD 3.20 billion in 2022 and USD 4.69 billion by 2032.
Key Competitors in the Overactive Bladder Therapeutics Industry:
1. Pfizer Inc.: Built in 1848. One of the biggest pharmaceutical companies in the world, Pfizer with yearly sales of around $50 billion (excluding COVID-19 product sales). The company used to sell a wide variety of chemicals and healthcare items, but today the majority of its sales come from prescription medications and vaccinations. United States headquarters. Today, Truveta and Pfizer established a collaborative partnership to give ongoing safety insights based on scalable, verified real-world data.
2. Johnson & Johnson: Johnson & Johnson Development - JJDC - was a venture capital fund run by Johnson & Johnson Innovation. The fund is based in New Brunswick, New Jersey, and it makes investments in the United States. It focused on healthcare devices and supplies, pharmaceuticals and biotechnology, and life science. The company was founded in 1978. In 1978, the headquarters were established. Johnson & Johnson's Janssen Pharmaceutical Companies announced in 2020 that it will expand its existing collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
3. Aurobindo Pharma Ltd.: Aurobindo Pharma Ltd is a manufacturer of speciality and generic drugs. The company's product offering includes a wide range of therapeutic areas. The United States generates the great bulk of the company's sales, followed by Europe. Founded 1986. Hyderabad is the headquarters.
4. Astellas Pharma Inc.: Astellas Pharma Inc is a pharmaceutical company that sells its goods all over the world. The majority of the company's revenue comes from Japanese markets, which are followed by the Americas. Royalty income accounts for a modest portion of Astellas' total sales. Oncology is its most profitable therapeutic field, followed by urology and transplantation. It was founded in 1894. Tokyo is the headquarters. Astellas and Pantherna Sign a New Technology Evaluation Agreement for Expanded Target Organ Research to Generate mRNA-Based Regenerative Medicine Programmes Using Direct Reprogramming.
5. Merck & Co. Inc.: Merck manufactures pharmaceuticals for a variety of therapeutic areas, including cardiometabolic disorders, cancer, and infections. Within cancer, the company's immuno-oncology platform is becoming a significant contributor to overall sales. It was founded in 1891. Rahway, New Jersey, is the company's headquarters. Lynparza and the prospective medication selumetinib are developed and commercialised independently by AstraZeneca and Merck in combination with the businesses' respective PD-L1/PD-1 immuno-oncology treatments Imfinzi and Keytruda.
6. Mylan NV: Generic pharmaceutical product developer and producer designed to fulfil the growing need for effective drugs. Established in 1961, with headquarters in England, United Kingdom. Lupin Limited (Lupin) and Mylan N.V., a worldwide pharmaceutical business, announced today that they will collaborate to commercialise a biosimilar of Enbrel®.
Definition: Overactive bladder is a condition in which the bladder squeezes urine out at the wrong time.
